^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCND1 expression

    i
    Other names: CCND1, BCL1, D11S287E, PRAD1, U21B31, Cyclin D1
    Entrez ID:
    595
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (SHINE ) (NCT01776840)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2013
    Primary completion :
    06/01/2021
    Completion :
    06/01/2024
    CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 expression
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma (NCT05976763)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/08/2023
    Primary completion :
    08/31/2038
    Completion :
    08/31/2038
    CCND1
    |
    Chr t(11;14) • CCND1 expression
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection (NCT03834740)
    Phase 1
    St. Joseph's Hospital and Medical Center, Phoenix
    Completed
    Last update posted :
    05/10/2024
    Initiation :
    12/21/2018
    Primary completion :
    02/18/2022
    Completion :
    02/18/2022
    PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B
    |
    PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression
    |
    everolimus • Kisqali (ribociclib)
    Study of Tazemetostat in Lymphoid Malignancies (NCT05983965)
    Phase 1
    University of Alabama at Birmingham
    Not yet recruiting
    Last update posted :
    05/08/2024
    Initiation :
    08/01/2024
    Primary completion :
    06/01/2028
    Completion :
    12/01/2029
    CD4
    |
    Chr t(11;14) • CCND1 expression
    |
    Calquence (acalabrutinib) • Tazverik (tazemetostat)
    Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044)
    Phase 1
    Juno Therapeutics, a Subsidiary of Celgene
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/06/2016
    Primary completion :
    05/10/2024
    Completion :
    05/10/2024
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LYMA-101) (NCT02896582)
    Phase 2
    The Lymphoma Academic Research Organisation
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    10/01/2016
    Primary completion :
    03/01/2019
    Completion :
    03/01/2025
    CD20 • CCND1 • CD5
    |
    Chr t(11;14) • CD20 expression • CCND1 expression
    |
    cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan
    Niraparib in High-grade Endometrial Cancer Trial (NIREC) (NCT05289648)
    Phase 1
    Sir Mortimer B. Davis - Jewish General Hospital
    Not yet recruiting
    Last update posted :
    02/01/2024
    Initiation :
    05/01/2024
    Primary completion :
    10/31/2025
    Completion :
    01/31/2026
    TP53 • CCND1 • CASP3 • CDKN1A
    |
    CCND1 expression
    |
    Zejula (niraparib)
    Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405) (NCT03834688)
    Phase 2
    PrECOG, LLC.
    Active, not recruiting
    Last update posted :
    01/23/2024
    Initiation :
    01/13/2020
    Primary completion :
    10/20/2022
    Completion :
    11/01/2024
    CCND1
    |
    Chr t(11;14) • CCND1 expression
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • bendamustine
    A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer (NCT03327064)
    Phase 1/2
    University of Alabama at Birmingham
    Withdrawn
    Last update posted :
    12/27/2023
    Initiation :
    10/01/2020
    Primary completion :
    08/01/2023
    Completion :
    08/01/2023
    CCND1
    |
    CCND1 expression
    |
    UAB30
    Abemaciclib and Letrozole to Treat Endometrial Cancer (GOG-3039) (NCT04393285)
    Phase 2
    Gynecologic Oncology Group
    Active, not recruiting
    Last update posted :
    12/13/2023
    Initiation :
    10/10/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20
    |
    CCND1 expression • CCND1 mutation
    |
    Verzenio (abemaciclib) • letrozole
    Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage (NCT02290145)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    11/22/2023
    Initiation :
    12/01/2016
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    CCND1
    |
    CCND1 overexpression • CCND1 expression • CCND1-H
    |
    cisplatin • docetaxel • 5-fluorouracil
    A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro) (NCT03906669)
    Phase 2
    St Vincent's Hospital
    Recruiting
    Last update posted :
    11/22/2023
    Initiation :
    03/20/2018
    Primary completion :
    04/01/2024
    Completion :
    04/01/2024
    HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3
    |
    HER-2 negative • CCND1 expression
    |
    tamoxifen • letrozole